echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Express delivery of more than half of patients with ulcerative colitis that has been relieved for nearly 3 years, and Janssen IL-12/23 inhibitor has a positive long-term effect

    Express delivery of more than half of patients with ulcerative colitis that has been relieved for nearly 3 years, and Janssen IL-12/23 inhibitor has a positive long-term effect

    • Last Update: 2021-08-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Johnson & Johnson's Janssen company (Janssen) announced its IL-12/IL-23 inhibitor Stelara (ustekinumab) for the treatment of moderate to severe active ulcerative colitis (UC) patients with long-term extended research data
    .


    The data showed that more than half (55.



    Ustekinumab developed by Janssen is a humanized IL-12 and IL-23 antibody
    .


    IL-12 and IL-23 are important cytokines that regulate the immune system and immune-mediated inflammatory diseases in the human body



    "Despite substantial progress in recent years, many UC patients are still struggling to seek sustained relief of symptoms, especially treatments that do not require steroids
    .


    " said Dr.
    Bruce E.


    Reference materials:

    Reference materials:

    [1] STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.